We are pleased to announce that Jennifer Che, Managing Director of Eagle IP, will be traveling to London from May 2 to May 6, 2026  in conjunction with the International Trademark Association (INTA) 2026 Annual Meeting..

If you or your team will be attending INTA2026 or will be in London during the first week of May, Jennifer would welcome the opportunity to meet for a coffee or a scheduled briefing. Please contact us to coordinate a time during the conference week.

我们的过去活动

Recommended Insights

Foreigners Beware: China Proposes Requiring IP Made Using Exported Chinese Genetic Resources to be Co-Owned by Chinese Collaborators

2023年3月22日
Proposed Examination Guidelines for the New Chinese Patent Law – Topic 2: Genetic Resource Restriction How Will the Tightened Genetic Resource Restrictions Affect Your IP In 2019-2021, China’s Ministry of Science and Technology (“MOST”, or the Science Ministry) established several laws and regulations with respect to biosafety1 and human genetic resources management2 (collectively referred as […]

CNIPA Releases Interim Measures for the Amended Chinese Patent Law Going Into Effect June 1, 2021

2021年5月28日
Breaking News! We finally have more details about the new Chinese Patent Law which will go into effect on June 1, 2021. The full set of measure can be found at this link. Below are some pertinent points. No Implementation Rules . . . . Yet The new Implementation Rules will not be available by […]

IP Strategies for the Newly Released Implementation Regulations of the 4th Amendment of the Chinese Patent Law: Part 3: The 15-Day Mailing Period is Mostly Going Away

2024年2月28日
A Closer Look at the New Presumed Receipt Date Calculation Background China has finally released the long-awaited Patent Law Implementation Regulations (“Regulations”) and associated "Patent Examination Guidelines" (“Guidelines”, similar to the United States' MPEP) which provide further clarity and details of the new Chinese patent law. Today’s article will focus on changes that impact how […]
Tapentadol.svg

Polymorph Patents in China: What is the Standard for Inventiveness for New Crystal Forms?

2020年7月14日
This case is focused on polymorphs, namely what are the standards for novelty and inventiveness when it comes to new crystal forms of a known drug? A recent Supreme People’s Court decision in China is illustrative of the way Chinese courts are thinking about polymorph patents in China. Grünenthal is a German pharmaceutical company and […]
Top crossarrow-right